Literature DB >> 32267000

Patterns of heart injury in COVID-19 and relation to outcome.

Ajay Kumar Mishra1, Kamal Kant Sahu1, Amos Lal2, Jennifer Sargent3.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32267000      PMCID: PMC7262038          DOI: 10.1002/jmv.25847

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   20.693


× No keyword cloud information.
To the Editor, We read with much interest the article “Analysis of heart injury laboratory parameters in 273 COVID‐19 patients in one hospital in Wuhan, China” by Han et al as published in March 2020. In this retrospective, single‐center study authors have discussed the role of acute cardiovascular injury marker including creatine kinase myocardial band (CK‐MB), myoglobulin, cardiac troponin I (cTnI), and NT‐proBNP on the outcome of 273 patients with COVID‐19 disease. Authors have suggested that elevated concentrations of these enzymes in venous blood were related to disease severity and poor outcome. We believe that this topic is relevant and evolving. We have the following additional comments for further understanding of the disease and its various pathophysiological bases in cardiac involvement. Nonischemic and ischemic myocardial injury has been attributed to be the two principle pathophysiological basis of acute cardiac injury in COVID‐19 patients. Of the two, nonischemic myocardial injury is predominant and is secondary to multiple secondary mechanisms. The various distinct mechanisms for nonischemic myocardial injuries that have been published in the literature are (a) cytokine storm as documented by significantly raised inflammatory markers, (b) secondary to hemophagocytic lymphohistiocytosis, (c) viral myocarditis with reports of progression to fulminant myocarditis, (d) stress cardiomyopathy, and (e) hypoxia‐induced cardiac myocyte apoptosis. , , Markers of cardiac injury including CK‐MB, myoglobin, lactate dehydrogenase, ultra‐TnI, NT‐proBNP, D‐dimer are elevated in any of the above patterns of cardiac injury. However, in most studies of COVID‐19 patients showing increased mortality, an elevated troponin I level has been uniformly associated with uncontrolled inflammation secondary to cytokine storm. This phenomenon of infection‐related increased cytokine release is identified by an elevated plasma level of several inflammatory markers. Various inflammatory markers that are shown to be elevated in patients with COVID‐19‐related cardiac injury are C‐reactive protein (CRP), procalcitonin, ferritin, D‐dimer, Interleukin‐2 (IL‐2), Interleukin‐7 (IL‐7), granulocyte‐colony stimulating factor, IgG‐induced protein 10, chemokine ligand 3, and tumor necrosis α. , , Did the authors have the details of various inflammatory markers among their patients? Not only that cytokine storm‐related cardiac injury has been consistently reported in most studies, but it has also been identified to be predictors of complications like acute respiratory distress, acute kidney injury, the severity of illness, requirement of intensive care unit admission, and higher mortality. , ,

CONFLICT OF INTERESTS

The authors declare that there are no conflict of interests.
  8 in total

1.  Cardiac drugs and outcome in COVID-19.

Authors:  A K Mishra; K K Sahu; J Sargent
Journal:  QJM       Date:  2020-07-01

Review 2.  COVID-19 and Cardiovascular Disease.

Authors:  Kevin J Clerkin; Justin A Fried; Jayant Raikhelkar; Gabriel Sayer; Jan M Griffin; Amirali Masoumi; Sneha S Jain; Daniel Burkhoff; Deepa Kumaraiah; LeRoy Rabbani; Allan Schwartz; Nir Uriel
Journal:  Circulation       Date:  2020-03-21       Impact factor: 29.690

3.  Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China.

Authors:  Shaobo Shi; Mu Qin; Bo Shen; Yuli Cai; Tao Liu; Fan Yang; Wei Gong; Xu Liu; Jinjun Liang; Qinyan Zhao; He Huang; Bo Yang; Congxin Huang
Journal:  JAMA Cardiol       Date:  2020-07-01       Impact factor: 14.676

4.  COVID-19 and the cardiovascular system.

Authors:  Ying-Ying Zheng; Yi-Tong Ma; Jin-Ying Zhang; Xiang Xie
Journal:  Nat Rev Cardiol       Date:  2020-05       Impact factor: 32.419

5.  Coronavirus disease-2019: An update on third coronavirus outbreak of 21st century.

Authors:  K K Sahu; A K Mishra; A Lal
Journal:  QJM       Date:  2020-05-01

6.  The clinical characteristics of myocardial injury in severe and very severe patients with 2019 novel coronavirus disease.

Authors:  Bo Zhou; Jianqing She; Yadan Wang; Xiancang Ma
Journal:  J Infect       Date:  2020-03-21       Impact factor: 6.072

Review 7.  Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic.

Authors:  Elissa Driggin; Mahesh V Madhavan; Behnood Bikdeli; Taylor Chuich; Justin Laracy; Giuseppe Biondi-Zoccai; Tyler S Brown; Caroline Der Nigoghossian; David A Zidar; Jennifer Haythe; Daniel Brodie; Joshua A Beckman; Ajay J Kirtane; Gregg W Stone; Harlan M Krumholz; Sahil A Parikh
Journal:  J Am Coll Cardiol       Date:  2020-03-19       Impact factor: 24.094

8.  Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan, China.

Authors:  Huan Han; Linlin Xie; Rui Liu; Jie Yang; Fang Liu; Kailang Wu; Lang Chen; Wei Hou; Yong Feng; Chengliang Zhu
Journal:  J Med Virol       Date:  2020-04-15       Impact factor: 20.693

  8 in total
  12 in total

1.  India Fights Back: COVID-19 Pandemic.

Authors:  Kamal Kant Sahu; Ajay Kumar Mishra; Amos Lal; Shamendra Anand Sahu
Journal:  Heart Lung       Date:  2020-04-23       Impact factor: 2.210

Review 2.  Coagulopathy, endothelial dysfunction, thrombotic microangiopathy and complement activation: potential role of complement system inhibition in COVID-19.

Authors:  Xin Wang; Kamal Kant Sahu; Jan Cerny
Journal:  J Thromb Thrombolysis       Date:  2020-10-15       Impact factor: 2.300

Review 3.  Current Perspectives of convalescent plasma therapy in COVID-19.

Authors:  Kamal Kant Sahu; Ajay Kumar Mishra; Manish Raturi; Amos Lal
Journal:  Acta Biomed       Date:  2020-11-10

Review 4.  An Update on Pulmonary Hypertension in Coronavirus Disease-19 (COVID-19).

Authors:  Ajay Mishra; Amos Lal; Kamal Kant Sahu; Anu Anna George; Kevin Martin; Jennifer Sargent
Journal:  Acta Biomed       Date:  2020-11-10

5.  Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis.

Authors:  Wenjie Tian; Wanlin Jiang; Jie Yao; Christopher J Nicholson; Rebecca H Li; Haakon H Sigurslid; Luke Wooster; Jerome I Rotter; Xiuqing Guo; Rajeev Malhotra
Journal:  J Med Virol       Date:  2020-07-11       Impact factor: 20.693

Review 6.  COVID-19: Specific and Non-Specific Clinical Manifestations and Symptoms: The Current State of Knowledge.

Authors:  Jacek Baj; Hanna Karakuła-Juchnowicz; Grzegorz Teresiński; Grzegorz Buszewicz; Marzanna Ciesielka; Ryszard Sitarz; Alicja Forma; Kaja Karakuła; Wojciech Flieger; Piero Portincasa; Ryszard Maciejewski
Journal:  J Clin Med       Date:  2020-06-05       Impact factor: 4.241

Review 7.  Trajectory of the COVID-19 pandemic: chasing a moving target.

Authors:  Kamal Kant Sahu; Ajay Kumar Mishra; Amos Lal
Journal:  Ann Transl Med       Date:  2020-06

Review 8.  Heart failure in COVID-19 patients: Critical care experience.

Authors:  Kevin John John; Ajay K Mishra; Chidambaram Ramasamy; Anu A George; Vijairam Selvaraj; Amos Lal
Journal:  World J Virol       Date:  2022-01-25

9.  Disease Severity Affects Ventricular Repolarization Parameters in Patients With COVID-19.

Authors:  Mevlut Koc; Hilmi Erdem Sumbul; Erdinc Gulumsek; Hasan Koca; Yurdaer Bulut; Emre Karakoc; Tuba Turunc; Edip Bayrak; Huseyin Ali Ozturk; Muhammed Zubeyir Aslan; Abdullah Orhan Demirtas; Yahya Kemal Icen
Journal:  Arq Bras Cardiol       Date:  2020-11       Impact factor: 2.000

Review 10.  Coronavirus disease-19 and cardiovascular disease: A risk factor or a risk marker?

Authors:  Jing Liu; Salim S Virani; Mahboob Alam; Ali E Denktas; Ihab Hamzeh; Umair Khalid
Journal:  Rev Med Virol       Date:  2020-09-22       Impact factor: 11.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.